← Eichor
Study identifier: NCT07329686 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.

Condition: Herpes Simplex Keratitis · Corneal Neovascularization  ·  Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

PhasePhase 1/Phase 2
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Corneal stromal injection is an emerging local drug delivery method, characterized by strong targeting, high drug concentration, and prolonged duration of action. It has been preliminarily applied in the treatment of fungal keratitis and neurotrophic corneal diseases. This study aims to investigate the safety and efficacy of anti-VEGF drugs delivered via corneal stromal injection in neovascularization caused by HSK (Herpes Simplex Keratitis). The study has clear medical significance and technical feasibility, and it is expected to promote innovation in the treatment paradigm for corneal neovascularization.

This description comes directly from the study's public registry record.

Talk to the study team

Xiuming Jin  ·  8613989455778  ·  lzyjxm@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

1 Xihu Avenue, Shangcheng District,Hangzhou, Zhejiang,China,Hangzhou, Zhejiang CompletedHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07329686